Cofoe Medical released its 2026 half-year report. In the first half, revenue reached 2.072 billion yuan, up 38.51% year on year. Net profit attributable to the parent company was 202 million yuan, up 20.84%, and non-GAAP net profit was 173 million yuan, up 26.73%. Core categories accelerated their volume growth, with revenue from the top five single products rising 50% year on year. Ventilators performed particularly well, with second-quarter sales exceeding 100 million yuan. In the first half, respiratory support revenue was 267 million yuan, up 166.90% year on year. The company launched a new-generation AI ventilator, the C11, helping move the product into home sleep health management scenarios. Other categories also maintained growth. Revenue from traditional Chinese medicine therapy and other businesses rose 114.54% year on year, while rehabilitation aids, medical care, and health monitoring grew 31.74%, 20.68%, and 11.70% respectively. The company continued to introduce new products, established an artificial intelligence research institute, and cooperated with partners including Royal Philips, Huawei Device, and Tencent Cloud. Seventeen products have now been connected to the HarmonyOS ecosystem. Overseas revenue in the first half was 210 million yuan, up 117% year on year. The company listed on the main board of the Hong Kong Stock Exchange on May 6, forming a dual capital platform across A-shares and H-shares.
Tencent Holdings Ltd
Koninklijke Philips NVCofoe Medical Technology Co.Ltd.Cofoe Medical reported H1 revenue up 38.51% and net profit up 20.84%, a strong earnings result.
